Filing Details

Accession Number:
0000899243-20-030060
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-30 21:54:12
Reporting Period:
2020-10-30
Accepted Time:
2020-10-30 21:54:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX () 1231
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1015747 Joseph Lewis C/o Cay House, Ep Taylor Drive
Lyford Cay
New Providence C5 N7776
No No Yes No
1266427 M Ivan Lieberburg 12860 El Camino Real, Suite 300
San Diego CA 92130
No No Yes No
1465835 Christopher Fuglesang 12860 El Camino Real, Suite 300
San Diego CA 92130
No No Yes No
1465836 Boxer Asset Management Inc. C/o Cay House, Ep Taylor Drive N7776
Lyford Cay
New Providence C5
No No Yes No
1465837 Boxer Capital, Llc 12860 El Camino Real, Suite 300
San Diego CA 92130
No No Yes No
1465914 I. Aaron Davis 12860 El Camino Real, Suite 300
San Diego CA 92130
Yes No Yes No
1468223 Mva Investors, Llc 11682 El Camino Real, Suite 320
San Diego CA 92130
No No Yes No
1663609 Bharatha Shehan Dissanayake 12860 El Camino Real, Suite 300
San Diego CA 92130
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-10-30 37,050 $202.00 216,288 No 4 S Direct
Common Stock Acquisiton 2020-10-30 37,051 $0.00 253,339 No 4 M Direct
Common Stock Disposition 2020-10-30 1 $219.97 253,338 No 4 F Direct
Common Stock Disposition 2020-10-30 362,950 $202.00 1,404,610 No 4 S Direct
Common Stock Acquisiton 2020-10-30 362,952 $0.00 1,765,562 No 4 M Direct
Common Stock Disposition 2020-10-30 2 $219.97 1,765,560 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant (right to purchase) Disposition 2020-10-30 362,952 $5.60 362,952 $0.00
Common Stock Warrant (right to purchase) Disposition 2020-10-30 37,051 $5.60 37,051 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
128,805 2017-01-06 No 4 M Direct
13,996 2017-01-06 No 4 M Direct
Footnotes
  1. These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital.
  2. (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
  3. These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
  4. The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.